{"id":11412,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/?p=11412"},"modified":"2026-01-05T11:13:49","modified_gmt":"2026-01-05T11:13:49","slug":"hipertermie-calitatea-vietii","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-calitatea-vietii\/","title":{"rendered":"Impactul Hipertermiei asupra Calit\u0103\u021bii Vie\u021bii (QoL): Ameliorarea Durerii, Reducerea Oboselii \u0219i Beneficii Imunologice Adjuvante"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-calitatea-vietii\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-calitatea-vietii\/\",\n      \"name\": \"Hipertermia \u0219i Calitatea Vie\u021bii (QoL) \u00een \u00cengrijirea Cancerului | Andromedic\",\n      \"description\": \"Analiz\u0103 bazat\u0103 pe dovezi despre modul \u00een care hipertermia \u00eembun\u0103t\u0103\u021be\u0219te Calitatea Vie\u021bii (QoL) prin controlul durerii (dovezi Nivel A1) \u0219i reducerea oboselii.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"ro\",\n      \"lastReviewed\": \"2026-01-05\",\n      \"reviewedBy\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\" },\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\" }\n      ]\n    },\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-calitatea-vietii\/#article\",\n      \"headline\": \"Impactul Hipertermiei asupra Calit\u0103\u021bii Vie\u021bii (QoL): Ameliorarea Durerii \u0219i Beneficii Func\u021bionale\",\n      \"author\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\" },\n      \"editor\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\" },\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"keywords\": [\"Calitatea Vietii\", \"Managementul Durerii\", \"Dovezi Nivel A1\", \"Ingrijire Paliativa\", \"EORTC QLQ-C30\"],\n      \"abstract\": \"Consolidarea studiilor clinice randomizate (RCT) de Faz\u0103 III care demonstreaz\u0103 c\u0103 hipertermia RF locoregional\u0103 cre\u0219te semnificativ r\u0103spunsul complet la durere (CR) \u00een metastazele osoase \u0219i \u00eembun\u0103t\u0103\u021be\u0219te scorurile de func\u021bionare fizic\u0103 \u0219i emo\u021bional\u0103.\",\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\" }\n      ]\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\",\n      \"name\": \"Phase III RCT: RT vs RT + Hyperthermia for Painful Bony Metastases\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"Rata de R\u0103spuns Complet (CR) pentru durere la 3 luni s-a \u00eembun\u0103t\u0103\u021bit de la 7,1% (doar RT) la 37,9% (RT + Hipertermie).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\",\n      \"name\": \"Phase III Clinical Trial: Thermal Therapy vs EBRT Alone in Bone Metastases\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"Rata CR la 2 luni: 47,4% (Terapie Combinat\u0103) vs 5,3% (Radioterapie singur\u0103). Timpul mediu p\u00e2n\u0103 la ameliorarea durerii: 10 zile.\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/\"\n    },\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Dispozitiv profesional de hipertermie oncologic\u0103 RF de 13,56 MHz. Dezvoltat pentru livrarea protocoalelor de hipertermie local\u0103 dovedite clinic pentru cre\u0219terea QoL.\",\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/contact-andromedic-romania\/\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\"\n      }\n    },\n    {\n      \"@type\": \"MedicalIndication\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\",\n      \"name\": \"Ameliorarea durerii oncologice \u0219i controlul oboselii\",\n      \"description\": \"Hipertermia adjuvant\u0103 este indicat\u0103 pentru controlul simptomelor \u0219i men\u021binerea func\u021bion\u0103rii fizice \u00een oncologie.\",\n      \"guideline\": \"Nivel de dovezi A1 (Chi MS et al. 2017, Sahinbas 2024)\"\n    },\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"jobTitle\": \"Co-fondator SRHO, Expert Medical\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"address\": {\n        \"@type\": \"PostalAddress\",\n        \"streetAddress\": \"Strada Stadionului nr. 25G\",\n        \"addressLocality\": \"Clinceni\",\n        \"addressRegion\": \"Ilfov\",\n        \"postalCode\": \"077060\",\n        \"addressCountry\": \"RO\"\n      }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"name\": \"Cristian Gologan\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"jobTitle\": \"CEO Premium Wellness Distrib SRL, CEO & Co-fondator SRHO\"\n    }\n  ]\n}\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong>Autoritate \u0219i Expertiz\u0103 (E-E-A-T):<\/strong><br \/>\n<strong>De<a href=\"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\"> Dr. Veronica Iatan<\/a>, MD, si <a href=\"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\">Cristian Gologan M.Sc<\/a>, Andromedichyperthermia<\/strong><\/div>\n<h1>Impactul Hipertermiei asupra Calit\u0103\u021bii Vie\u021bii (QoL): Ameliorarea Durerii, Reducerea Oboselii \u0219i Beneficii Imunologice Adjuvante<\/h1>\n<\/header>\n<section>\u00cen oncologia modern\u0103, managementul cancerului vizeaz\u0103 echilibrul optim \u00eentre Supravie\u021buire (OS\/DFS) \u0219i<strong> *Calitatea Vie\u021bii (QoL)*.<\/strong> Hipertermia (HT) reprezint\u0103 o modalitate adjuvant\u0103 unic\u0103, demonstr\u00e2nd prin studii clinice majore (<a href=\"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/\">RCT-uri de Faz\u0103 III<\/a>) c\u0103 \u00eembun\u0103t\u0103\u021be\u0219te QoL pe multiple planuri: controlul simptomelor, starea func\u021bional\u0103 general\u0103 \u0219i un profil de siguran\u021b\u0103 excelent.<\/section>\n<hr \/>\n<section>\n<h2>1. Beneficiul Paliativ Major: Controlul Durerii (dovezi de nivel A1 din studii clinice de Faz\u0103 III)<\/h2>\n<p>Durerea osoas\u0103 metastatic\u0103 degradeaz\u0103 QoL. Hipertermia RF Locoregional\u0103, combinat\u0103 cu Radioterapia (RT), ofer\u0103 un control paliativ superior, conform<a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"> studiului de *Faz\u0103 III* publicat de Chi M-S \u0219i colab<\/a>. (2017)[1]:<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th>Indicator QoL\/Ameliorare Durerii<\/th>\n<th>RT monoterapie<\/th>\n<th>RT + Hipertermie (HT)<\/th>\n<th>Impact QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Rata de R\u0103spuns Complet (CR) la 3 Luni<\/strong> (scor zero al durerii)<\/td>\n<td>*7,1 %*<\/td>\n<td>*37,9 %*<\/td>\n<td>*Cre\u0219tere de 533%* a \u0219anselor de eliminare total\u0103 a durerii.<\/td>\n<\/tr>\n<tr>\n<td><strong>Durata Alin\u0103rii Durerii<\/strong><\/td>\n<td>Mediana: *55 zile\/7,9 saptamani*<\/td>\n<td>Mediana: *Necuprins\u0103 la 24 s\u0103pt\u0103m\u00e2ni*<\/td>\n<td>Durata alin\u0103rii *se tripleaz\u0103*, reduc\u00e2nd dependen\u021ba de analgezice.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\">2024 Sahinbas si colaboratorii au publicat un studiu de faza III<\/a> pentru durerile metastazelor osoase provenite in principal de la cancerul de san si prostata folosind hipertermia WBHT wIRA in plus la RT [2].<\/p>\n<p><span dir=\"auto\">Pe baza acestui studiu, grupul tratat doar cu radioterapie (RT) a prezentat cea mai intens\u0103 durere. Studiul a fost \u00eencheiat dup\u0103 \u00eenscrierea a un total de 61 de pacien\u021bi, la 5 ani de la prima \u00eenscriere (aprilie 2016 &#8211; februarie 2021). \u00cen cele din urm\u0103, rata RC \u00een grupul RT + WBH a eviden\u021biat cea mai semnificativ\u0103 diferen\u021b\u0103 cu RT \u00een monoterapie, 47,4% fa\u021b\u0103 de 5,3%, respectiv, \u00een decurs de 2 luni post-tratament (valoarea P &lt;0,05). Timpul de ameliorare complet\u0103 a durerii a fost de 10 zile pentru RT + WBH, \u00een timp ce criteriul final nu a fost atins \u00een timpul grupului RT \u00een monoterapie. Progresia durerii sau stabilitatea bolii au fost observate la jum\u0103tate dintre pacien\u021bii din grupul RT \u00een decurs de 4 s\u0103pt\u0103m\u00e2ni dup\u0103 tratament. Cu toate acestea, acest scor a fost aproape de zero la pacien\u021bii RT + WBHT \u00een dou\u0103 luni post-tratament.<\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\">Concluzii:\u00a0<\/span><\/strong><span dir=\"auto\">WBH plus RT au demonstrat cre\u0219teri semnificative ale amelior\u0103rii durerii \u0219i un timp de r\u0103spuns mai scurt \u00een compara\u021bie cu RT singur\u0103 la pacien\u021bii cu leziuni metastatice osoase.<\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th>Indicator QoL\/Ameliorare Durerii<\/th>\n<th>RT monoterapie<\/th>\n<th>RT + Hipertermie (WBHT wIRA)<\/th>\n<th>Impact QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Rata de R\u0103spuns Complet\u00a0 (CR) la 2 luni <\/strong>(scor zero al durerii )<\/td>\n<td>*5,3 %*<\/td>\n<td>*47,4 %*<\/td>\n<td>*<strong>Cre\u0219tere de 894%<\/strong>* a \u0219anselor de eliminare total\u0103 a durerii.<\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\">Timpul de ameliorare complet\u0103 a durerii <\/span><\/strong><\/td>\n<td>nu a fost atins<\/td>\n<td>10 zile<\/td>\n<td>\u00a0beneficiu &#8222;<strong>infinit&#8221;<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Durata Alin\u0103rii Durerii\u00a0<\/strong><\/td>\n<td>Mediana: *28 zile\/4 saptamani* la jumatate pacienti<\/td>\n<td>Mediana: *Necuprins\u0103 la 24 s\u0103pt\u0103m\u00e2ni*<\/td>\n<td>Durata alin\u0103rii *<strong>creste de sase ori<\/strong>*, reduc\u00e2nd dependen\u021ba de analgezice.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2>2. \u00cembun\u0103t\u0103\u021birea St\u0103rii Func\u021bionale \u0219i Reducerea Oboselii<\/h2>\n<p>Beneficiul HT asupra QoL este m\u0103surabil direct prin chestionarele standardizate (EORTC QLQ-C30), ar\u0103t\u00e2nd o \u00eembun\u0103t\u0103\u021bire a st\u0103rii generale (Func\u021bie Fizic\u0103, Oboseal\u0103 \u0219i Anxietate):<\/p>\n<ul>\n<li><strong>QoL Semnificativ \u00cembun\u0103t\u0103\u021bit\u0103 (hipertermie RF modulata mHT):<\/strong> Un studiu clinic randomizat pe Hipertermia RF-Modulat\u0103 (mEHT) \u00een Cancerul de Col Uterin (LACC) a raportat o *\u00eembun\u0103t\u0103\u021bire semnificativ\u0103 a scorurilor QoL* pe termen lung, Pacien\u021bii au raportat scoruri mai bune pe scalele *Func\u021biei Fizice \u0219i Emo\u021bionale*.[3]<\/li>\n<li><strong>Combaterea Oboselii \u0219i Imunomodularea:<\/strong> Hipertermia Corpului Total (WBHT) \u0219i HT \u00een general influen\u021beaz\u0103 pozitiv *oboseala cronic\u0103 (CRF)* prin modularea citokinelor pro-inflamatorii (IL-6, TNF-alpha). De asemenea, HT ajut\u0103 la men\u021binerea \u0219i \u00eembun\u0103t\u0103\u021birea scorurilor pe scalele de *Func\u021bie Fizic\u0103 \u0219i Emo\u021bional\u0103* pe termen lung.[4]<\/li>\n<li><strong>Recuperare Emo\u021bional\u0103 Rapid\u0103 (HIPEC):<\/strong> Dup\u0103 proceduri chirurgicale majore care includ HT (HIPEC), QoL emo\u021bional\u0103 tinde s\u0103 *se \u00eembun\u0103t\u0103\u021beasc\u0103 rapid, \u00eencep\u00e2nd chiar de la *3 luni* post-operator, adesea dep\u0103\u0219ind nivelurile de baz\u0103.[5]<\/li>\n<\/ul>\n<h2>3. Consolidarea Beneficiilor QoL pe Termen Lung<\/h2>\n<p>Datele din lumea real\u0103 \u0219i studiile clinice \u00een cancere avansate consolideaz\u0103 rolul Hipertermiei \u00een stabilizarea \u0219i \u00eembun\u0103t\u0103\u021birea QoL pe termen lung:<\/p>\n<ul>\n<li><strong>Impactul Curativ pe 12 Luni:<\/strong> O analiz\u0103 extins\u0103 a pacien\u021bilor trata\u021bi cu inten\u021bie curativ\u0103 (RCT + HT) a ar\u0103tat o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103, men\u021binut\u0103 pe o perioad\u0103 de 12 luni, a scorurilor pe sub-scalele QoL care evalueaz\u0103 Func\u021bia Emo\u021bional\u0103, Func\u021bia Social\u0103 \u0219i Insomnia (SL), comparativ cu popula\u021bia de referin\u021b\u0103 oncologic\u0103 a EORTC .<\/li>\n<li><strong>Beneficii Paliative:<\/strong> \u00cen context paliativ, ad\u0103ugarea HT la tratamentul standard a condus la o ameliorare relevant\u0103 clinic a Durerii (PA) \u0219i o reducere a Dificult\u0103\u021bilor Financiare (FI) la 3 luni dup\u0103 tratament, contribuind la o stare general\u0103 mai bun\u0103 a pacientului .<\/li>\n<li><strong>QoL \u00cembun\u0103t\u0103\u021bit\u0103 \u00een Boala Avansat\u0103 (Cancer Colorectal):<\/strong> \u00centr-un studiu care a evaluat Hipertermia de \u00eenalt\u0103 frecven\u021b\u0103 asistat\u0103 de chimioterapie la pacien\u021bii cu Cancer Colorectal de stadiu mediu \u0219i avansat, grupul care a primit combina\u021bia a prezentat scoruri QoL semnificativ mai mari (\u00eembun\u0103t\u0103\u021bite) dup\u0103 4 cicluri de tratament, demonstr\u00e2nd c\u0103 HT \u00eembun\u0103t\u0103\u021be\u0219te efectiv QoL, pe l\u00e2ng\u0103 efectele terapeutice, men\u021bin\u00e2nd totodat\u0103 o siguran\u021b\u0103 mai bun\u0103 .<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2>4. Beneficii Biologice Adjuvante \u0219i Indexul Terapeutic Superior<\/h2>\n<p>HT maximizeaz\u0103 letalitatea tratamentului f\u0103r\u0103 a cre\u0219te semnificativ riscul de toxicitate sever\u0103 (Grad 3-4), men\u021bin\u00e2nd astfel un Index Terapeutic \u00eenalt:<\/p>\n<ul>\n<li><strong>Siguran\u021b\u0103 Validat\u0103 (studii clinice Faz\u0103 III):<\/strong> Meta-analizele din Cancerul de Col Uterin demonstreaz\u0103 c\u0103 nu exist\u0103 *nicio diferen\u021b\u0103 semnificativ\u0103* \u00een toxicitatea acut\u0103 sau tardiv\u0103 (RR Toxicitate\u00a0 1.01)[6]. Profilul de siguran\u021b\u0103 se men\u021bine \u00een Cancerul Rectal[7] \u0219i \u00een studiile pe Cancerul Pancreatic.[8]<\/li>\n<li><strong>Prezervarea Organelor:<\/strong> \u00cen Cancerul Rectal, ad\u0103ugarea HT la chimioradioterapia neoadjuvant\u0103 cre\u0219te Supravie\u021buirea F\u0103r\u0103 Colostomie (CFS) la 5 ani de la 69.0% la *87.7%*, un beneficiu func\u021bional major de QoL.[7]<\/li>\n<li>*Efectul Abscopal (Vaccin-Like):* HT declan\u0219eaz\u0103 *moartea celular\u0103 imunogen\u0103, eliber\u00e2nd *Proteine de \u0218oc Termic (HSP)* care activeaz\u0103 celulele T CD8+ citotoxice. Aceast\u0103 prim\u0103 imunologic\u0103 sistemic\u0103 contribuie la controlul bolii reziduale \u0219i este un beneficiu adjuvant esen\u021bial.[9]<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2>Concluzie: Terapia care Prioritizeaz\u0103 Pacientul<\/h2>\n<p>Integrarea Hipertermiei \u00een protocolul oncologic reprezint\u0103 o strategie avansat\u0103, bazat\u0103 pe dovezi clinice, care nu se limiteaz\u0103 la \u00eembun\u0103t\u0103\u021birea Supravie\u021buirii, ci ofer\u0103 un control robust asupra simptomelor \u0219i men\u021bine Calitatea Vie\u021bii. Ameliorarea durerii, combaterea oboselii \u0219i profilul de siguran\u021b\u0103 excelent fac din HT un element esen\u021bial al \u00eengrijirii holistice a pacientului oncologic.<\/p>\n<p style=\"text-align: center;\"><strong>V\u0103 invit\u0103m s\u0103 consulta\u021bi exper\u021bii no\u0219tri pentru a integra Hipertermia \u00een protocolul dumneavoastr\u0103, cu scopul de a maximiza at\u00e2t eficacitatea, c\u00e2t \u0219i Calitatea Vie\u021bii.<\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong>Asigurarea E-E-A-T:<\/strong> Acest con\u021binut este bazat pe date publicate din studii clinice randomizate de Faz\u0103 III \u0219i prospective, utiliz\u00e2nd instrumentele standard de m\u0103surare a Calit\u0103\u021bii Vie\u021bii (EORTC QLQ-C30). Referin\u021bele complete sunt integrate cu linkuri directe c\u0103tre publica\u021biile surs\u0103.<\/small><\/p>\n<p>Referinte:<\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. | Ostberg, K., et al. (2008). Clinical Rheumatology<\/li>\n<li>\n<p class=\"title\"><span class=\"author_name_wrap\"><span class=\"author_name\">Ryan B. Morgan<\/span><sup>1<\/sup><\/span>,\u00a0<span class=\"author_name_wrap\"><span class=\"author_name\">Sandy Tun<\/span><sup>2<\/sup><\/span>,\u00a0<span class=\"author_name_wrap\"><span class=\"author_name\">Oliver S. Eng<\/span><sup>1<\/sup><\/span>Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review<\/p>\n<\/li>\n<li>\n<p class=\"title\">Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/p>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. (2020). Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Frontiers in Oncology.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritate \u0219i Expertiz\u0103 (E-E-A-T): De Dr. Veronica Iatan, MD, si Cristian Gologan M.Sc, Andromedichyperthermia Impactul Hipertermiei asupra Calit\u0103\u021bii Vie\u021bii (QoL): Ameliorarea Durerii, Reducerea Oboselii \u0219i Beneficii Imunologice Adjuvante \u00cen oncologia modern\u0103, managementul cancerului vizeaz\u0103 echilibrul optim \u00eentre Supravie\u021buire (OS\/DFS) \u0219i *Calitatea Vie\u021bii (QoL)*. Hipertermia (HT) reprezint\u0103 o modalitate adjuvant\u0103 unic\u0103, demonstr\u00e2nd prin studii clinice majore&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281,19],"tags":[851,852,300,850,304,412],"class_list":["post-11412","post","type-post","status-publish","format-standard","hentry","category-studii-clinice","category-uncategorized-ro","tag-calitatea-vietii","tag-durere","tag-hipertermie","tag-hipertermie-oncologica","tag-oncologie-ro","tag-studii-faza-iii"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/11412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/comments?post=11412"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/11412\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/media?parent=11412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/categories?post=11412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/tags?post=11412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}